Wenying Yu

2.7k total citations
80 papers, 2.0k citations indexed

About

Wenying Yu is a scholar working on Molecular Biology, Oncology and Materials Chemistry. According to data from OpenAlex, Wenying Yu has authored 80 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 21 papers in Oncology and 11 papers in Materials Chemistry. Recurrent topics in Wenying Yu's work include Cytokine Signaling Pathways and Interactions (16 papers), Synthesis and biological activity (5 papers) and Magnetic and transport properties of perovskites and related materials (5 papers). Wenying Yu is often cited by papers focused on Cytokine Signaling Pathways and Interactions (16 papers), Synthesis and biological activity (5 papers) and Magnetic and transport properties of perovskites and related materials (5 papers). Wenying Yu collaborates with scholars based in China, United States and Japan. Wenying Yu's co-authors include Jiayuh Lin, Chenglong Li, Xiang Gao, Jun Zhang, Ling‐Yi Kong, Lide Zhang, Maode Lai, Lingyi Kong, Xiaobing Wang and Wenda Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Wenying Yu

78 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wenying Yu China 25 816 482 309 283 268 80 2.0k
Xiaojing Zhao China 28 1.1k 1.4× 265 0.5× 465 1.5× 356 1.3× 270 1.0× 115 3.0k
Sunyoung Park South Korea 27 782 1.0× 421 0.9× 240 0.8× 137 0.5× 316 1.2× 107 2.3k
Tianhui Hu China 31 1.4k 1.7× 364 0.8× 297 1.0× 172 0.6× 229 0.9× 111 2.7k
Jong Wook Park South Korea 28 869 1.1× 309 0.6× 112 0.4× 159 0.6× 220 0.8× 121 2.5k
Xiang Gao China 31 1.1k 1.4× 453 0.9× 337 1.1× 161 0.6× 375 1.4× 95 2.8k
Cuiping Liu China 28 1.3k 1.5× 470 1.0× 169 0.5× 89 0.3× 471 1.8× 142 2.7k
Shaofeng Duan China 27 792 1.0× 165 0.3× 263 0.9× 189 0.7× 148 0.6× 84 1.9k
Yanhua Fan China 22 467 0.6× 142 0.3× 252 0.8× 228 0.8× 73 0.3× 95 1.4k
Shili Xu United States 25 1.1k 1.4× 639 1.3× 85 0.3× 190 0.7× 340 1.3× 61 2.4k

Countries citing papers authored by Wenying Yu

Since Specialization
Citations

This map shows the geographic impact of Wenying Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenying Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenying Yu more than expected).

Fields of papers citing papers by Wenying Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenying Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenying Yu. The network helps show where Wenying Yu may publish in the future.

Co-authorship network of co-authors of Wenying Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Wenying Yu. A scholar is included among the top collaborators of Wenying Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenying Yu. Wenying Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Wenying, et al.. (2025). Characterization of rectus femoris lesions in knee osteoarthritis at different stages and the effect of ultrasound-guided acupotomy. Frontiers in Physiology. 15. 1496425–1496425. 2 indexed citations
2.
Yu, Wenying, Min‐Hsiung Pan, Alvin Chao‐Yu Chen, et al.. (2025). Leveraging the Modified Early Warning Score (MEWS) in rapid response teams to predict and prevent ICU readmissions. Journal of the Formosan Medical Association.
3.
Hu, Yuxuan, et al.. (2024). New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs. Journal of Medicinal Chemistry. 67(14). 11522–11542. 3 indexed citations
5.
Rao, D. C., et al.. (2024). Construction of a hydrophilic porphyrin-based MOF@COF hybrid via post-synthetic modification for N-glycopeptides analysis in human serum. Analytical Methods. 16(47). 8188–8193. 4 indexed citations
6.
Yu, Wenying, et al.. (2023). Dynamics of the splicing factor SRSF6 protein show metastable conformations with potentially druggable sites revealed by Markov state model. Chemical Physics Letters. 837. 141059–141059. 1 indexed citations
7.
Liu, Yakun, Hongwei Liu, Wenying Yu, et al.. (2023). Room temperature magnetocaloric effect and electrical transport properties of CoFeVGa Heusler alloys undergoing martensitic transformation. Journal of Alloys and Compounds. 948. 169573–169573. 2 indexed citations
8.
Liu, Zhe, Liang Ma, Yiming Sun, Wenying Yu, & Xue Wang. (2021). Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death and Disease. 12(6). 561–561. 38 indexed citations
9.
Zhang, Jing, et al.. (2021). Primary Exophytic Extraskeletal Osteosarcoma of the Liver: A Case Report and Literature Review. Risk Management and Healthcare Policy. Volume 14. 1009–1014. 6 indexed citations
10.
Wang, Huan, Zhe Liu, Jiankang Li, et al.. (2020). LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis. Pharmacological Research. 153. 104661–104661. 20 indexed citations
11.
Liu, Zhe, et al.. (2019). LL1, a novel and highly selective STAT3 inhibitor, displays anti‐colorectal cancer activities in vitro and in vivo. British Journal of Pharmacology. 177(2). 298–313. 24 indexed citations
12.
Yu, Wenying, et al.. (2019). A Single-Cell Immunofluorescence Method for the Division Patterns Research of Mouse Bone Marrow-Derived Hematopoietic Stem Cells. Stem Cells and Development. 28(14). 954–960. 3 indexed citations
13.
Yu, Wenying, Dongmei Song, Wenda Zhang, et al.. (2019). Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors. European Journal of Medicinal Chemistry. 174. 236–251. 57 indexed citations
14.
Wang, Xiaofang, Fang Dong, Sen Zhang, et al.. (2018). TGF-β1 Negatively Regulates the Number and Function of Hematopoietic Stem Cells. Stem Cell Reports. 11(1). 274–287. 37 indexed citations
15.
Yu, Wenying, Chenglong Li, Wenda Zhang, et al.. (2017). Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking. Journal of Medicinal Chemistry. 60(7). 2718–2731. 41 indexed citations
16.
Wan, Ledong, Wenying Yu, Enhui Shen, et al.. (2017). SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 68(1). 118–129. 134 indexed citations
17.
Zhang, Wenda, Shanshan Li, Ting Ma, et al.. (2017). Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy. Scientific Reports. 7(1). 46352–46352. 37 indexed citations
18.
Wang, Xiaobing, et al.. (2014). Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters. 24(10). 2368–2373. 10 indexed citations
19.
Xiao, Hui, Hemant K. Bid, David Jou, et al.. (2014). A Novel Small Molecular STAT3 Inhibitor, LY5, Inhibits Cell Viability, Cell Migration, and Angiogenesis in Medulloblastoma Cells. Journal of Biological Chemistry. 290(6). 3418–3429. 54 indexed citations
20.
Liu, Aiguo, Yan Liu, Zhenghu Xu, et al.. (2011). Novel small molecule, XZH‐5, inhibits constitutive and interleukin‐6‐induced STAT3 phosphorylation in human rhabdomyosarcoma cells. Cancer Science. 102(7). 1381–1387. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026